UNSPSC 51191531: Azolimine

This classification denotes a diuretic with the molecular formula C10H11N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DES29595KX, chemically known as 4-imidazolidinone, 2-imino-3-methyl-1-phenyl- but generally known as azolimine, which bears US NIH Compound Identifier 38684. European Medicines Agency schedules Azolimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05662MIG.

UNSPSC 51191531 Azolimine (Commodity) covers chemical supply for municipal water treatment and facility operations, though the recent solicitation activity under this code shows a divergence from the nominal commodity name. The City of Meriden's IFB B027-15, posted July 8, 2026 with bids due July 29, 2026, solicits sodium bisulfite chemical supply for its Water Pollution Control Facility—a direct water treatment chemical procurement evaluated on unit cost for estimated volumes. Pricing firmness, performance and payment bonds, and specified insurance minimums (General Liability $1–$2 million, Auto Liability $1 million, Umbrella/Excess coverage) are typical requirements. A second opportunity tagged under this code—the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with proposals due March 26, 2026—addresses a substantially different scope involving FDA-compliant pharmaceutical distribution through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health 110 and 112, Morris & Dickson) across participating state and local government facilities in Minnesota and Oregon, with a contract term of two years effective July 1, 2026. The pharmaceutical RFP is unrelated to the code's stated azolimine scope and likely reflects a tagging misalignment.

Activity under this code is sparse and geographically limited. The water-treatment chemical procurement originates in Connecticut, while the MMCAP cooperative purchasing vehicle spans Minnesota and Oregon. Recent opportunities show issuing bodies at both municipal (City of Meriden) and state multistate cooperative (MMCAP, administered by Minnesota Department of Administration) levels. The pharmaceutical RFP emphasizes price competitiveness (75 percent weight), compliance with cGMP and DSCSA certification, EDI capability, and ability to sustain relationships with multiple authorized wholesalers, with performance penalties of $200–$1,500 per violation and a 3 percent administrative fee on all contract purchases. The water-treatment chemical opportunity is a straightforward unit-cost IFB with standard bonding and insurance requirements typical of municipal utility procurement.